Race Oncology Ltd has released a press release.
Quarterly Activity Report and Appendix 4C
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Racura Oncology
- Race Receives $5.25m RD Tax Refund for Financial Year 2024
- Race Submits Human Ethics for RC220 Phase 1 Trial
- Race Discovers Multiple Novel FTO Inhibitor Candidates
- Race Oncology Board Renewal Update
- Bisantrene Phase 2 AML Trial Successful Concludes
Later from Racura Oncology
- Race Signs Contract for Phase 1 Trial of RC220
- S&P DJI Announces March 2025 Quarterly Rebalance
- Ethics approval received for RC220 Phase 1 Trial
- Race Initiates First AU Site for Phase 1 Solid Tumour Trial
- RC220 Phase 1 Trial Opens for Patient Enrolment
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology